DiaMedica Therapeutics Inc. (DMAC) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Diamedic Therapeutics (DMAC) Q1 2026: R&D Expenses Rise 40% as Remedy 2 Stroke Trial Surpasses 70% Enrollment
May 07, 2026
-
Diomedica (DMAC) Q4 2025: R&D Spend Climbs 29% as Preeclampsia and Stroke Pipelines Advance
March 31, 2026
-
Diametica Therapeutics (DMAC) Q3 2025: Cash Position Jumps to $55M, Extending Runway to 2027
November 13, 2025
-
Diametica Therapeutics (DMAC) Q2 2025: $30M Capital Infusion Extends Runway to 2027 as Preeclampsia Data Advances
August 13, 2025
-
Diametica (DMAC) Q1 2025: R&D Spend Jumps 54% as Preeclampsia and Stroke Trials Accelerate
July 03, 2025